FIELD: biotechnology, immunology, virology, genetics and molecular biology.
SUBSTANCE: invention relates to the field of biotechnology, immunology, virology, genetics and molecular biology. An isolated recombinant receptor-binding domain of glycoprotein S (RBD-S) of the SARS-CoV-2 virus is presented. Described is a pharmaceutical composition based on AAV5 for the induction of specific immunity to the SARS-CoV-2 virus and/or the prevention of coronavirus infection caused by SARS-CoV-2, and its use for the induction of specific immunity to the SARS-CoV-2 virus and/or the prevention of coronavirus infection caused by SARS-CoV-2.
EFFECT: improvement of pharmaceutical composition for the induction of specific immunity to the SARS-CoV-2.
3 cl, 7 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
| GENE CONSTRUCT FOR THE EXPRESSION OF RECOMBINANT PROTEINS BASED ON THE SEGMENT OF THE SARS-COV-2 S-PROTEIN, INCLUDING RBD AND SD1, FUSED WITH THE FC FRAGMENT OF IGG, A METHOD OF OBTAINING RECOMBINANT PROTEINS, ANTIGENS AND ANTIGENIC COMPOSITIONS FOR THE INDUCTION OF LONG-TERM ANTIBODY AND CELLULAR IMMUNITY AGAINST SARS-CO-2 | 2021 |
|
RU2802825C2 |
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
| ADVANCED CORONAVIRUS VACCINE | 2022 |
|
RU2816182C2 |
| MESSENGER RNA VACCINES AGAINST WIDE RANGE OF CORONAVIRUS VARIANTS | 2022 |
|
RU2826172C2 |
